Suppr超能文献

糖尿病患者高血压管理的实用方法

A Practical Approach to Hypertension Management in Diabetes.

作者信息

Shaikh Altamash

机构信息

Department of Endocrinology, Saifee Hospital, Mumbai, India.

出版信息

Diabetes Ther. 2017 Oct;8(5):981-989. doi: 10.1007/s13300-017-0310-3. Epub 2017 Sep 19.

Abstract

Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and disability and leads to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes, treating hypertension should be a primary consideration. Practical approaches to hypertension in diabetes, including individualized targets are discussed, as per stage and complication of diabetes, according to current studies and guidelines. Angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARBs) are the most effective drugs for treating hypertension in diabetes, in the absence of contraindications. Calcium antagonists or diuretics are acceptable as second-line agents. Once the target is achieved, antihypertensive drugs should be continued. Newer antidiabetes medications such as sodium glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) have antihypertensive properties and may assist in treatment decision-making.

摘要

高血压是糖尿病最重要的合并症之一,对死亡和残疾有显著影响,并导致大血管和微血管并发症。在评估糖尿病患者的医疗重点时,治疗高血压应是首要考虑因素。根据当前研究和指南,针对糖尿病不同阶段和并发症,讨论了糖尿病高血压的实用治疗方法,包括个体化目标。在没有禁忌证的情况下,血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)是治疗糖尿病高血压最有效的药物。钙拮抗剂或利尿剂可作为二线药物。一旦达到目标,应继续使用抗高血压药物。新型抗糖尿病药物,如钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)、胰高血糖素样肽1受体激动剂(GLP1-RA)和二肽基肽酶4抑制剂(DPP4i)具有降压特性,可能有助于治疗决策。

相似文献

1
A Practical Approach to Hypertension Management in Diabetes.糖尿病患者高血压管理的实用方法
Diabetes Ther. 2017 Oct;8(5):981-989. doi: 10.1007/s13300-017-0310-3. Epub 2017 Sep 19.

引用本文的文献

10
SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication.SIRT1 拮抗糖尿病血管并发症中的氧化应激。
Front Endocrinol (Lausanne). 2020 Nov 16;11:568861. doi: 10.3389/fendo.2020.568861. eCollection 2020.

本文引用的文献

3
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
8
Current and Future Treatment of Hypertension in the SPRINT Era.SPRINT时代高血压的当前及未来治疗
Methodist Debakey Cardiovasc J. 2015 Oct-Dec;11(4):206-13. doi: 10.14797/mdcj-11-4-206.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验